Pharma Journalist -

Amicus Therapeutics and the Perelman School of Medicine at the University of Pennsylvania (Penn) announced a major expansion to their collaboration with rights to pursue collaborative…
Read More...

SMi Group are delighted to announce that industry expert Mary-Beth Joshi, Director, Duke University Medial Centre will lead a pre-conference workshop in London on the 24th September.…
Read More...

Almac Sciences, a member of the Almac Group, announced the appointment of Dr Sheryl Foster to the position of Vice President of Quality, reporting to Managing Director & President,…
Read More...

Teva Pharmaceutical Industries Ltd., announced the launch of a generic version of Ranexa (ranolazine) Extended-Release Tablets, 500 mg and 1000 mg, in the U.S. Ranolazine…
Read More...

Eli Lilly and Company announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing…
Read More...

Celgene Corporation announced the U.S. Food and Drug Administration (FDA) approved REVLIMID (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult…
Read More...

Pfizer Inc. announced that a Phase 3 study to assess the use of LYRICA (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized…
Read More...

AveXis, a Novartis company, announced innovative access programs for Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than 2 years of age with…
Read More...

Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi (ruxolitinib) for the treatment of steroid-refractory acute GVHD in adult and pediatric…
Read More...

Pfizer Inc. announced that a Phase 3 study to assess the use of LYRICA (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized…
Read More...